Singapore Maps 10,000 Proteomes for Precision Medicine

Singapore is taking a giant leap toward personalized medicine by creating an unprecedented map of how proteins behave in the human body.

The PRECISE-SG100K initiative will analyze blood samples from 10,000 Singaporean residents using advanced proteomics technology from Seer and Thermo Fisher Scientific. This ambitious project is part of a larger effort to study 100,000 people, combining genetic data, lifestyle information, medical imaging, and now deep protein analysis.

Why study proteins? While genes provide the blueprint for life, proteins do the actual work in our bodies. Understanding how proteins function differently across populations could reveal why certain diseases affect Asian populations differently than others.

The study focuses on Singapore's multi-ancestry Asian population, filling a critical gap in medical research. Most large-scale health studies have historically centered on European populations, leaving doctors with incomplete information about how diseases develop and respond to treatment in Asian communities.

Researchers will combine data from multiple cutting-edge platforms to create what they're calling one of the most complete multiomic datasets ever assembled. This integrated approach means scientists can connect the dots between someone's genes, their proteins, their environment, and their health outcomes.

The Ripple Effect

The implications extend far beyond Singapore's borders. Biomarker discoveries from this study could help doctors worldwide better predict and prevent cardiometabolic diseases, vision disorders, and neurological conditions in Asian populations.

Dr. John Chambers, chief scientific officer of PRECISE, explained that the goal is revealing "how genetics, environment, and lifestyle shape disease risk and treatment response." This knowledge could help doctors identify who's at risk for specific diseases years before symptoms appear.

The technology being used can detect thousands of proteins in a single blood sample, offering an incredibly detailed snapshot of someone's health. Previous population studies using these combined technologies have already demonstrated the power of high-throughput, deep proteome coverage.

Seer CEO Dr. Omid Farokhzad called PRECISE-SG100K "one of the most ambitious and carefully designed multiomic health initiatives in the world." The company designed its Proteograph platform specifically for population-scale studies like this one.

The data generated will support multiple research efforts simultaneously, from discovering new disease markers to validating existing diagnostic tests and building predictive models for assessing individual disease risk.

Singapore's investment in understanding its population's unique health profile represents a broader shift toward precision medicine that accounts for genetic diversity. As this database grows and researchers make new discoveries, the benefits will extend to Asian communities globally and advance personalized healthcare for everyone.